A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma

被引：3

作者：

Ramachandran, Indu R. ^{[1
]}

Lin, Cindy ^{[1
]}

Chase, Tess ^{[2
]}

Gabrilovich, Dmitry ^{[1
]}

Nefedova, Yulia ^{[1
]}

机构：

[1] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA

[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

10.1182/blood.V124.21.5729.5729

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Isatuximab based combinations induce potent tumor growth inhibition in pre-clinical models of multiple myeloma and acute lymphocytic leukemia
Zhu, Chen
Nicolazzi, Celine
Van de Velde, Helgi
Wiederschain, Dmitri
Sidhu, Sukhvinder
Chiron, Marielle
CANCER RESEARCH, 2020, 80 (16)
[22] HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML
Boyd-Kirkup, Jerome
Thakkar, Dipti
Brauer, Peter
Zhou, Jianbiao
Chng, Wee-Joo
Ingram, Piers Jamie
BLOOD, 2017, 130
[23] Discovery of highly selective DUB inhibitors with in vivo pre-clinical anti-tumor activity
Jacq, Xavier
Martin, Niall M. B.
Smith, Lisa
Harrigan, Jeanine
Knights, Charlotte
Robinson, Helen
Ofir-Rosenfeld, Yaara
Cranston, Aaron
Kemp, Mark I.
Jackson, Stephen P.
CANCER RESEARCH, 2015, 75
[24] Anti-tumor activity of pamidronate in human multiple myeloma
Kondo, H
Mori, A
LEUKEMIA & LYMPHOMA, 2002, 43 (04) : 919 - 921
[25] Pre-clinical development of a novel anti-GPRC5D inducing potent anti-tumor effect through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for multiple myeloma
Bonnevaux, Helene
Remy, Elisabeth
Pizette, Theo
Bouvier, Sophie
Desrumeaux, Klervi
Bassinet, Laurent
Nicolazzi, Celine
Rettman, Pauline
Klippel, Zandra
Meloni, Marco
Chiron, Marielle
Virone-Oddos, Angela
CANCER RESEARCH, 2024, 84 (06)
[26] DOES COLOR OF AN ANTI-TUMOR AGENT PREDICT FOR CLINICAL ANTI-TUMOR ACTIVITY
VONHOFF, DD
KUHN, J
CLARK, G
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1981, 6 (01) : 93 - 94
[27] The SMAC Mimetic Lcl-161 Demonstrates Anti-Tumor Activity As a Single Agent and Decreases the Apoptotic Threshold of Chemotherapy Agents in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models
Runckel, Kyle
Mavis, Cory
Skitzki, Joseph
Czuczrnan, Myron S.
Hernandez-Ilizaliturri, Francisco J.
BLOOD, 2012, 120 (21)
[28] EXOSTING DEMONSTRATES POTENT ANTI-TUMOR ACTIVITY IN A MOUSE MODEL OF LEPTOMENINGEAL DISEASE
Feng, Xudong
Lin, John
Jang, Su Chul
Lule, Sevda
Sanchez-Jauregui, Paloma
Kirwin, Katherine
Zi, Tong
Kasera, Samuel
Siso, Silvia
Zhang, Kelvin
Patel, Shil
Sathyanarayanan, Sriram
Economides, Kyriakos
Broom, Wendy
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A796 - A796
[29] The FHP01 DDX3X Helicase Inhibitor Exerts Potent Anti-Tumor Activity In Vivo in Breast Cancer Pre-Clinical Models
Gherardini, Lisa
Inzalaco, Giovanni
Imperatore, Francesco
D'Aurizio, Romina
Franci, Lorenzo
Miragliotta, Vincenzo
Boccuto, Adele
Calandro, Pierpaolo
Andreini, Matteo
Tarditi, Alessia
Chiariello, Mario
CANCERS, 2021, 13 (19)
[30] SENTI-101, an allogeneic cell product, induces potent and durable anti-tumor immunity in pre-clinical models of peritoneal carcinomatosis
Junca, Alba Gonzalez
Lee, Gary
Nagaraja, Archana
Mullenix, Alyssa
Gordley, Russell
Frimannson, Daniel
Benabbas, Anissa
Lee, Chen-Ting
Truong, Tiffany
Quach, Allison
Tian, Mengxi
Savur, Rishi
Martinez, Rowena
Perry-McNamara, Alyssa
Wang, Don-Hong
Maller, Ori
Iyer, Dharini
Magal, Ashita
Huynh, Christina
Blanco, Carmina
Lin, Jack
Garrison, Brian
Lee, Philip
Lu, Timothy
Mangalampalli, Sravani
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

← 1 2 3 4 5 →